T-cell exhaustion may limit long-term immunity in COVID-19 patients
Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
List view / Grid view
Researchers suggest patients who develop mild COVID-19 may not be able to fight reinfection very effectively because their CD8+ T cells show signs of exhaustion.
The discovery of an inflammatory pathway promoting brain ageing and cognitive decline could lead to new treatments for age-related conditions.
This tissue-specific handbook brings you key publications, in-house protocols and troubleshooting recommendations for your organoid cell culture.
Using synthetic chemistry, researchers have fused hydrophobic adjuvants with water-soluble proteins to create a new type of vaccine.
According to a Public Health England study, prior SARS-CoV-2 infection provides 83 percent protection against reinfection but may not stop individuals spreading COVID-19.
By combining nanobodies targeting different regions of the SARS-CoV-2 Spike protein, researchers were able to protect cells from infection.
A new protein-based nanoparticle vaccine protected mice against a variety of coronaviruses, researchers have shown.
A team has found immune cells in the lungs after infection from the flu, which protected mice against reinfection from a different strain.
This webinar from Bio-Techne demonstrates how to use a novel in vitro flow cytometry-based assay to monitor SARS-CoV-2 binding to ACE-2.
Dr H. Michael Shepard, CEO and CSO of Enosi Life Sciences, discusses the similarities between cancer and autoimmune diseases, highlighting how this knowledge could be used to enhance treatments.
Researchers suggest that identifying new treatments for autoimmune diseases requires studying the immune system AND target tissues together.
A new analysis suggests SARS-CoV-2-specific antibodies remain relatively stable for eight months and Spike protein-specific memory B cells increase in number over time.
Discover how workflows are being accelerated to speed up the vaccine research and development process while maintaining safety and immunogenicity.
Associate Professor Pandurangan Vijayanand from La Jolla Institute for Immunology discusses his study into the body’s immune response to SARS-CoV-2 and why this can vary.
Scientists have created a prognostic classification model which uses biomarkers to help predict an individual’s risk of developing severe COVID-19 symptoms.